Key Points
- Biotechnology innovator argenx is expanding its use of Cradle’s end-to-end AI-driven protein engineering platform, granting more scientists and research teams access following successful initial results.
- Cradle’s software has successfully assisted argenx in optimizing existing lead compounds and generating novel antibody candidates targeting multiple complex properties, including target affinity and selectivity.
- By running successive design, test, and learn loops independently, argenx scientists have been able to explore novel sequence spaces beyond traditional starting candidates and accelerate the progression of promising molecular designs.
- Bas Van Der Woning, Head of Discovery at argenx, emphasized that the collaboration aims to deliver better medicines to patients with a heightened sense of urgency.
- Stef van Grieken, CEO and Co-Founder of Cradle, noted that the partnership reflects a broader industry shift toward putting generative AI tools directly into the hands of scientists who possess deep biological expertise.
- Cradle operates globally with bases in Amsterdam, Netherlands, and Zürich, Switzerland, backed by major institutional investors including IVP, Index Ventures, and Kindred Capital.
NETHERLANDS (Amsterdam Times News) — November 17, 2026 — Biotechnology company argenx is scaling up its deployment of Cradle’s artificial intelligence-powered protein engineering platform across a wider array of discovery programs and scientific teams. As announced by software developer Cradle, the expansion builds directly upon successful preliminary work that utilized machine learning models to optimize therapeutic antibody candidates and explore uncharted sequence spaces for autoimmune disease treatments.
How Has Cradle’s AI Platform Supported argenx’s Antibody Discovery Pipeline?
As announced by Cradle, initial deployments of its software allowed argenx researchers to refine existing lead molecules and design new antibody candidates with precise specifications across multiple characteristics, such as target binding affinity and selectivity. Through iterative cycles of design, testing, and active learning, scientists navigated sequence spaces that lay far beyond the reach of conventional trial-and-error screening.
Highlighting the operational impact of the partnership, Bas Van Der Woning, Head of Discovery at argenx, stated as reported in the corporate announcement: “Every advance in how we discover and develop antibodies is about getting better medicines to people who need them with a sense of urgency.”
Bas Van Der Woning further stated: “Our scientists have used Cradle’s AI platform to explore designs well beyond their starting candidates, with each round of experiments improving the next round of designs. As we expand access to the platform across our discovery teams, we look forward to applying it to more programs.”
The broadened integration supports argenx’s overarching mission to translate fundamental discoveries in immunology into advanced, highly specific antibody-based medicines, allowing high-performing molecules to transition more efficiently from early discovery into preclinical development.
What Do Industry Leaders Say About the Expanded Collaboration?
The partnership underscores a wider transition within the biopharmaceutical sector toward embedding machine learning directly into day-to-day laboratory workflows. As reported in the platform announcement, Stef van Grieken, CEO and Co-Founder of Cradle, underscored the significance of placing computational tools directly into the control of research scientists.
As stated by Stef van Grieken: “argenx is one of the most innovative antibody developers in the world, and we’re excited to see more of its scientists using Cradle across their discovery programs. That’s the shift we’re building for: AI in the hands of the scientists who know the biology best, getting smarter with every experiment they run.”
Cradle’s proprietary software architecture combines active learning from empirical assay data, multi-property optimization, and generative modeling into a unified infrastructure. Operating out of its primary hubs in Amsterdam and Zürich, the company supports over 80 active R&D programmes spanning global pharmaceutical, industrial biotechnology, and agricultural sectors.
Background of the Particular Development
The integration of artificial intelligence into protein engineering represents a major paradigm shift in modern drug discovery. Historically, optimizing therapeutic antibodies required years of painstaking, iterative wet-lab experimentation to balance competing biophysical properties such as thermal stability, expression yield, and binding affinity. In recent years, generative machine learning models trained on vast repositories of amino-acid sequences and proprietary laboratory data have transformed this trial-and-error approach into a predictive science. Collaborations such as the one between Cradle and argenx reflect the maturation of software-as-a-service (SaaS) platforms in biotech, where biopharmaceutical firms integrate third-party AI infrastructure to compress early-stage development timelines and improve the developability of complex biologic drugs.
Prediction
This expanded collaboration is expected to accelerate the progression of argenx’s robust immunological pipeline, potentially shortening the timeline required to nominate pre-clinical development candidates for severe autoimmune conditions. For the particular audience of biopharmaceutical researchers, protein engineers, and clinical development specialists, the success of scalable, scientist-driven AI platforms signals a broader industry transition where computational design becomes a standard operating baseline rather than an auxiliary tool. Over the coming years, such integrations will likely drive higher success rates in candidate optimization, reducing developmental attrition and shifting.